Background: The Japan Society of Hepatology guidelines indicate that hepatitis C virus (HCV) protease inhibitor combination therapy with simeprevir (SMV), pegylated-interferon (Peg-IFN), and ribavirin (RBV) is a therapeutic option for patients who fail to respond to a direct direct-acting antiviral-containing regimen. However, treatment outcomes have room for improvement. Fluvastatin (FLV) add-on treatment in Peg-IFN and RBV combination therapy for HCV-infected patients significantly improved the sustained virologic response (SVR), but the add-on effect of FLV on SMV combination therapy is not well understood.
INTRODUCTION
H EPATITIS C VIRUS (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. Recently, anti-HCV treatment has improved dramatically after the development of directacting antivirals (DAAs), which directly target HCV protein. Numerous clinical studies for patients with HCV infection have revealed that DAA combination therapy is highly effective and safe. [1] [2] [3] [4] Therefore, standard therapy for HCV infection has been changing from interferon (IFN)-based therapy to IFN-free DAA therapy. However, the use of IFN-free DAA therapy has been limited for patients, mainly because of limited resources in some countries. 5 In Italy, the use of IFN-free DAA therapy is limited to patients with advanced fibrosis. 5 In Japan, the Japan Society of Hepatology (JSH) guidelines indicate that HCV protease inhibitor combination therapy with simeprevir (SMV), pegylated-interferon (Peg-IFN), and ribavirin (RBV) is a therapeutic option for patients who fail a DAA-containing regimen; 6 however, the treatment outcomes have room to improve.
Simeprevir is a potent second-generation HCV nonstructural protein (NS)3/4 A protease inhibitor that shows high antiviral activity. In a Japanese phase III trial of SMV/Peg-IFN-α-2a/RBV combination therapy for genotype 1 HCV-infected patients (CONCERTO 1-3 study), the overall sustained viral response rate 12 weeks after the end of treatment (SVR12) was 73.0% (203/ 278). In addition, SVR12 rates were 88.6% (109/123), 44.3% (47/106), and 95.9% (47/49) in treatment naïve patients, non-responders, and patients who relapsed after previous IFN-based therapy, respectively. 7, 8 These clinical trial results indicated that these combination therapies were more tolerable and had comparable efficacy to first-generation HCV protease inhibitor combination therapy with telaprevir/Peg-IFN/RBV. 9, 10 However, the efficacy was not comparable to that of IFN-free DAA therapy. [2] [3] [4] 11 Statins are given as cholesterol synthesis inhibitors for patients with hyperlipidemia worldwide. Statins suppress mevalonic acid synthesis by inhibiting HMG-CoA reductase, thereby reducing cholesterol synthesis. In addition, most statins, including fluvastatin (FLV), suppress the synthesis of geranyl pyrophosphate. Geranyl pyrophosphates allow various proteins to be synthesized into geranylated proteins, some of which are essential for HCV replication. 12 In vitro HCV replication analysis indicated that statins suppressed HCV replication. 13, 14 In addition, the results of several clinical trials have indicated that adding a statin to Peg-IFN and RBV combination therapy improved treatment outcomes. 15, 16 In those reports, statin add-on treatment improved the SVR rate by more than 25% in some groups, including patients with the IL28B non-TT genotype. However, the effect of adding a statin to SMV, Peg-IFN, and RBV combination therapy has not been clarified.
In this prospective multicenter, randomized trial, we aimed to clarify the effect of adding a statin to SMV, Peg-IFN, and RBV combination therapy.
METHODS
Patients and study design I N THIS PROSPECTIVE, randomized multicenter study, a total of 61 patients with a genotype 1b HCV infection were enrolled between July 2014 and June 2016. Of those 61 patients, one patient withdrew written consent, therefore, a total of 60 patients were randomized into the Peg-IFN/RBV/SMV group (control group) or Peg-IFN/RBV/SMV plus FLV add-on group (FLV add-on group) (Fig. 1) .
Eligible patients had chronic genotype 1b hepatitis C infection and were 20-70 years old when informed consent was obtained. Patients who had liver cirrhosis, poorly controlled cardiac disease, creatinine clearance <50 mL/min, co-infection with hepatitis B virus or HIV, autoimmune disease, or a history of hypersensitivity to IFN, RBV, or HCV protease inhibitors were excluded. Enrolled patients were stratified and randomized according to gender, age, and institute. The NORTE Study Group consists of Hokkaido University Hospital (Sapporo, Japan) and associated hospitals in Japan and has undertaken clinical research in liver diseases.
1,2,10,17,18 All patients gave written informed consent before entry into this study. The clinical study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional ethics review committee of Hokkaido University Hospital and associated hospitals. This study was registered with the UMIN Clinical Trials Registry as UMIN000012878.
Treatment protocol
All enrolled patients were given Peg-IFN α-2a (Pegasys; Chugai Pharmaceutical, Tokyo, Japan) at a dose of 180 μg once a week for 24 weeks, daily RBV (Copegus; Chugai Pharmaceutical) for 24 weeks, and daily SMV (Sovriad; Janssen Pharmaceutical, Tokyo, Japan) at a dose of 100 mg for 12 weeks. The dose of RBV was determined according to the prescribing information (patients who weighed ≤60 kg received 600 mg daily, patients who weighed between 60 and 80 kg received 800 mg daily, and patients who weighed >80 kg received 1000 mg daily). If needed, the dose of Peg-IFN or RBV was adjusted by the attending doctor according to the prescribing information. In the FLV add-on group, patients were given daily FLV at a dose of 30 mg for 24 weeks.
Laboratory tests, physical findings, and definition of virologic response was completed. Physical findings and laboratory tests were carried out at all time points by the attending doctors. In addition, adverse events were monitored and managed at every assessment point by the attending doctors. IL28B rs8099917 was genotyped as previously described 19 and advanced liver fibrosis was defined as a Fibrosis-4 (FIB-4) index score >3.25.
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The primary end-point for this study was SVR at 24 weeks after treatment completion. Sustained virologic response was defined as undetectable HCV-RNA in the serum after the end of treatment. Virologic response was evaluated at 4, 8, 12, and 24 weeks after the initiation of treatment and 4, 12, and 24 weeks after treatment completion. Rapid viral response (RVR) and early 
Statistical analysis
We referred to previous reports 7, 8, 21 and hypothesized that the SVR rate would be 70% and would improve by 25% in the FLV add-on group 15 ,16 compared with the control group, with a one-sided α error of 0.05 and a power of 0.80. Therefore, the required sample size was estimated to be 36 cases in each group for this study.
Continuous variables were analyzed using the paired Mann-Whitney U-test. Categorical variables were analyzed using the χ 2 test. All P-values were two-tailed and the level of significance was set at P < 0.05. Statistical analyses were carried out using SPSS version 21.0 (IBM Japan, Tokyo, Japan). The sample size calculation was carried out using EZR. 22 
RESULTS

Patient characteristics
I N THIS MULTICENTER randomized study, 61 patients with a genotype 1b HCV infection were enrolled. Because one patient withdrew written consent, 60 patients were randomized into the control group or the FLV addon group. As shown in Figure 1 , 31 patients were assigned to the FLV add-on group and the remaining 29 patients were assigned to the control group. Baseline patient characteristics of both groups are shown in Table 1 . There were no significant differences among the clinical factors, including IL28B genotype, previous treatment response, and FIB-4 index.
Comparison of virologic response between control and FLV add-on groups
The RVR rates of patients in the control group and FLV add-on group were 93.5% (29/31) and 89.7% (26/29), respectively, and were not significantly different (P = 0.67). Similarly, the EVR and end of treatment response rates of patients in the control group and FLV add-on group were not significantly different (P = 0.51 and P = 0.59, respectively). The SVR4 rates of patients in the control group and FLV add-on group were 87.1% (27/31) and 86.2% (25/29), respectively. These results did not differ significantly between the groups (P = 0.56) (Fig. 2) . As shown in Figure 2 , the SVR rate gradually decreased in both groups and the SVR24 rates of patients in the control group and FLV add-on group were 77.4% (24/31) and 75.9% (22/29), respectively, and were not significantly different between the groups (P = 0.89).
Comparison of SVR24 rates of the control group and FLV add-on group according to clinical factors
We next compared the SVR24 rates between the control group and FLV add-on groups according to viral and host factors. As shown in Figure 3 , gender (Fig. 3a) , IL28B genotype (Fig. 3b) , FIB-4 index (Fig. 3c) , age (Fig. 3d) , previous treatment response (Fig. 3e) , baseline platelet count (Fig. 3f) , and baseline total cholesterol value (Fig. 3g) did not affect the different SVR24 rates in the control group and FLV add-on group. Table 2 shows adverse events and discontinuation in the FLV add-on group and control group. In the FLV add-on group, one patient (3.2%) discontinued treatment because of a psychological disorder, and in the control group, two patients (6.9%) discontinued treatment because of retinopathy or incidence of HCC. No significant difference in the incidence of treatment discontinuation was observed between the two groups. Additionally, no patient had a lethal adverse event during treatment in this study. In both groups, one patient (3.2% and 3.4% in FLV addon group and control group, respectively) experienced alanine aminotransferase elevation more than five times the upper limit of normal; however, the elevation normalized during treatment and the incidence of alanine aminotransferase elevation was not significantly different between the two groups. The most common adverse event in both Figure 2 Comparison of virologic response between hepatitis C genotype 1b-infected patients treated with pegylated-interferon/ ribavirin/simeprevir without (control group) or with fluvastatin (FLV add-on group). ETR, end of treatment response; EVR, early viral response; RVR, rapid viral response; SVR, sustained virologic response. groups was anemia, the incidence of which was not significantly different between the groups. DISCUSSION S EVERAL PREVIOUS REPORTS indicated that a statin added to Peg-IFN and RBV combination therapy for patients with HCV infection improved the SVR rate 15, 16 and suppressed virological relapse. 23 In contrast, in the present study, we did not observe any add-on effect when FLV was added to SMV, Peg-IFN, and RBV combination therapy. The reason no add-on effect was observed with SMV, Peg-IFN, and RBV combination therapy, in contrast to that observed with Peg-IFN and RBV therapy, has not been clarified; however, there are several hypotheses. Compared with Peg-IFN and RBV combination therapy, SMV, Peg-IFN, and RBV combination therapy achieved a higher SVR rate; therefore, there was no room for improvement in the SVR rate, especially in difficult-to treat-patients. Yokoyama et al. reported that pitavastatin added to Peg-IFN and RBV combination therapy resulted in a higher SVR rate in patients with total cholesterol <170 mg/dL or platelet count <15 (10 4 /μL). 24 However, in the present study, the SVR rate in patients with total cholesterol <170 mg/dL (Fig. 3g) or platelet count <15 (10 4 /μL) (Fig. 3f) was similar between the FLV add-on group and the control group. In the present study, the SVR rate in those patients was higher than that previously found after Peg-IFN and RBV therapy. 24 Therefore, there might not have been room for improvement in the SVR rate. Kohjima et al. 15 reported that, when eicosapentaenoic acid and a statin were added to Peg-IFN/RBV therapy for patients with HCV infection, the SVR rate improved remarkably in IL28B non-TT patients (SVR rates were 5.6% and 37.9% in the control group and add-on group, respectively). Similar to that of patients with a low platelet count, in the present study, the SVR rate in IL28B non-TT patients was higher than that previously observed after Peg-IFN and RBV therapy. 15, 24 Therefore, there might not have been room for improvement. The number of patients with IL28B non-TT was relatively limited, which might have affected the results. In addition, the results of a previous study indicated that statin add-on treatment suppressed virologic relapse. 23 In SMV/Peg-IFN/RBV combination therapy, patients that experienced virological relapse had resistance-associated variants (RAVs) of NS3 D168/E/ V. 18 The statin add-on effect might have been attenuated in patients with those RAVs.
Safety analysis
In the present study, patients who had the IL28B TT genotype and were treatment naïve, or experienced virologic relapse during a previous treatment, achieved an SVR rate of 85% (34/40). Numerous previous reports revealed that IFN therapy suppressed the occurrence of HCC. 25 Conversely, whether DAA therapy suppresses the occurrence of HCC has not been proven. In such an aspect, as described in the JSH guidelines, 6 in patients who would be expected to respond well to IFN therapy, such as patients with IL28B TT, SMV, Peg-IFN, and RBV combination therapy could be a therapeutic option. The JSH guidelines indicate that SMV/Peg-IFN/RBV is a therapeutic option for patients who fail NS5A inhibitor, daclatasvir, and HCV protease inhibitor, and asunaprevir combination therapy. 6 Because most patients who failed daclatasvir/asunaprevir had NS5A and NS3 RAVs, 17 we analyzed whether baseline RAVs affected the SVR rate in the present study. As shown in Table S1 , serum from 43 patients with an adequate amount of baseline stored serum was analyzed for baseline RAVs using a direct sequencing method as described previously. 18 As shown in Figure S1 , the SVR rate was similar regardless of baseline RAVs. Uchida et al. reported that, after failure to respond to daclatasvir and asunaprevir combination therapy, rare RAVs that were extremely tolerant to NS5A inhibitors were observed. 26 Therefore, retreatment with NS5A inhibitors, including regimens for those patients, might not result in a high SVR rate. Recently, Ozeki et al. reported successful retreatment with triple combination therapy containing SMV for two patients who failed to respond to daclatasvir and asunaprevir combination therapy. 27 Taken together with our results, SMV/Peg-IFN/RBV combination therapy might be a potential therapeutic option for patients who failed to respond to daclatasvir and asunaprevir combination therapy. However, the number of patients who had RAVs at baseline in the present study was limited and a larger number is required for a better analysis.
Recently Hashimoto et al. reported that serum lowdensity lipoprotein cholesterol (LDL-C) levels increased during IFN-free DAA treatment. 28 Therefore, we analyzed the change in serum LDL-C levels during and after treatment in patients who had an adequate amount of stored serum at baseline, 4 weeks after treatment initiation, end of treatment, and 24 weeks after treatment completion (FLV add-on group, n = 21; control group, n = 18). As shown in Figure S2 , serum LDL-C levels were significantly lower in both the FLV add-on group and control group 4 weeks after initiation of therapy and at the end of treatment than at baseline. However, serum LDL-C levels were significantly higher 24 weeks after treatment completion than at the end of treatment. Serum LDL-C levels were not significantly different between the FLV add-on group and control group at any time point; however, at the end of treatment, serum LDL levels tended to be lower in the FLV add-on group (median, 80.5 vs. 96.5 mg/dL; P = 0.052) than in the control group. We speculated that add-on FLV might affect LDL levels through its antihyperlipidemic effect. The different LDL-C levels between those receiving IFN-based therapy and those receiving IFN-free DAA therapy might result from the effect of IFN on decreased serum LDL through lipoprotein disorders. 29, 30 In the present study, the safety profile was not significantly different between the two groups ( Table 2) . Hepatitis C virus protease inhibitors, including SMV, are mainly metabolized by CYP3A; 31 therefore, when administering a drug that is metabolized by CYP3A, a drug-drug interaction may occur. Although most statins are metabolized through CYP3A, FLV is mainly metabolized by CYP2C9 and is less likely to interact with SMV. Therefore, in this study, increases in significant adverse events were not observed in the FLV add-on group.
There were several limitations in the present study. One notable limitation was that the included number of patients in the present study was less than the planned number because, after approval of IFN-free DAA therapy in Japan, the number of patients who were treated with IFN-based therapy was limited. Ethically, it was difficult to initiate SMV, Peg-IFN, and RBV therapy in patients eligible for IFN-free DAA therapy. Additionally, in the interim analysis, no superiority was observed in the FLV add-on group; therefore, we decided to stop enrolling patients into this study. However, if the initially planned number of patients were included, these results would not be improved.
In conclusion, the results of this prospective, multicenter, randomized study indicated that the addition of FLV to SMV, Peg-IFN, and RBV combination therapy for Table 2 Comparison discontinuation rate and adverse events between two groups of patients with genotype 1 hepatitis C virus infection treated with simeprevir/pegylated-interferon/ribavirin combination therapy (control) and fluvastatin (FLV add-on) FLV add-on group Control group P-value Number 31 29
All treatment discontinuation n (%) 1 (3.2) 2 (6.9) NS Adverse events ALT elevation
ALT, alanine transaminase; Cr, creatinine; Hg, hemoglobin; NS, not significant; Plt, platelet count; ULN, upper limit of normal.
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